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Abstract
High risk (oncogenic) human papillomavirus (HPV) infection causes cervical
cancer. Infections are common but most clear naturally. Persistent infection can
progress to cancer. Pre-neoplastic disease (cervical intraepithelial neoplasia/CIN)
is classified by histology (CIN1-3) according to severity. Cervical abnormalities are
screened for by cytology and/or detection of high risk HPV but both methods are
imperfect for prediction of which women need treatment. There is a need to
understand the host virus interactions that lead to different disease outcomes and
to develop biomarker tests for accurate triage of infected women. As cancer is
increasingly presumed to develop from proliferative, tumour initiating, cancer stem
cells (CSCs), and as other oncogenic viruses induce stem cell associated gene
expression, we evaluated whether presence of mRNA (detected by qRT-PCR) or
proteins (detected by flow cytometry and antibody based proteomic microarray)
from stem cell associated genes and/or increased cell proliferation (detected by
flow cytometry) could be detected in well-characterised, routinely collected cervical
samples from high risk HPV+ve women. Both cytology and histology results were
available for most samples with moderate to high grade abnormality. We found that
stem cell associated proteins including human chorionic gonadotropin, the
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oncogene TP63 and the transcription factor SOX2 were upregulated in samples
from women with CIN3 and that the stem cell related, cell surface, protein
podocalyxin was detectable on cells in samples from a subset of women with CIN3.
SOX2, TP63 and human gonadotrophin mRNAs were upregulated in high grade
disease. Immunohistochemistry showed that SOX2 and TP63 proteins clearly
delineated tumour cells in invasive squamous cervical cancer. Samples from
women with CIN3 showed increased proliferating cells. We believe that these
markers may be of use to develop triage tests for women with high grade cervical
abnormality to distinguish those who may progress to cancer from those who may
be treated more conservatively.
Introduction
The cancer stem cell (CSC) hypothesis [1] suggests that the bulk of transformed
cells within cancers have limited proliferative capacity and arise from a relatively
small fraction of CSCs which are capable of unlimited self-renewal. The CSCs are
thought to initiate the original tumour and any metastatic tumours. CSCs were
first identified in acute myeloid leukaemia [2] and have since been shown in many
solid tumours including melanoma [3, 4] and breast [5], pancreatic [6], lung [7],
head and neck [8], brain [9], colon [10, 11], prostate [12], and liver [13, 14]
cancers. CSCs often have complex phenotypes but have been characterised by
their expression of ‘‘stemness genes’’ including NANOG (OMIM: 607937), OCT4
(OMIM: 164177), SOX2 (OMIM: 184429) and podocalyxin (OMIM: 602632)
[15–18]. In virally induced cancers the action of viral proteins on host tissue cells
may alter expression of ‘‘stemness’’ genes and promote CSC development.
Hepatitis C virus infection has been reported to induce CSCs in human liver [19]
and the major EBV oncogene LMP1 was reported to induce a cancer stem cell
phenotype in nasopharyngeal epithelial cells [20]. Up-regulation of ‘‘stemness’’
gene protein expression in cancer can thus serve as an indicator of neoplastic
change.
Worldwide, nearly all cervical carcinomas are caused by known high risk
(oncogenic) types of Human Papilloma Virus (HR-HPVs) with the majority
attributed to persistent infection by HPV-16 or HPV-18 [21]. Cervical cancer and
its precursor stages of cervical intraepithelial neoplasia/CIN (graded 1–3
according to severity) typically occur in cells of the transformation zone where
columnar epithelium undergoes metaplastic change into squamous epithelium.
There is a need to better understand the host - virus interactions that lead to
different disease outcomes and to develop adjunct biomarker tests for more
accurate triage of infected women. CIN2 or worse is currently regarded as the
standard threshold for treatment of pre-neoplastic lesions. However, as treatment
itself carries a level of morbidity, it is of interest to determine more accurately
Biomarkers for Human Papillomavirus+ve Pre-Neoplastic Cervical Disease
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which women are at high risk of cancer development and which women might be
managed more conservatively.
Where implemented, cervical cancer screening programmes have reduced the
incidence of invasive disease by recognising and treating pre-invasive lesions.
Nevertheless there is still room for improvement, particularly in the selection of
cases which require treatment. Although most screening programmes involve
cytological examination of exfoliated cervical epithelial cells, molecular HPV
testing is being widely introduced to enhance sensitivity. A paradigm shift is
imminent whereby the primary screening modality for the future is likely to be
HPV testing. However, one significant issue even with clinically validated HPV
tests is their inability to determine which infections will result in significant
disease. Further, while the clinical sensitivity of HPV testing consistently exceeds
that of cytology, the specificity is less optimal. Thus there is a need to develop
adjunct triage tests for biomarkers that are more specific for detection of HPV
related high grade disease. To this end, we investigated whether there was an
association of CSC markers and/or cell proliferation that would differentiate HR-
HPV+ve high grade pre-neoplastic cervical disease from insignificant lesions in
cervical samples routinely taken for liquid based cytology (LBC) and for which
biopsy data was available. We further investigated expression of stem cell related
proteins in biopsies of HPV+ve squamous carcinoma of the cervix.
Materials and Methods
Ethics statement
Ethical approval was obtained from Scotland A Research Ethics Committee (REF
12/SS/0034). All cervical samples were collected into ThinPrep-preservcyt liquid
based cytology transport medium (Hologic, Crawley, UK). For this study, 95
anonymised, curated, cervical smear samples were obtained from the Scottish
National HPV archive, which holds Generic Scotland A Research Ethics
Committee approval for Research Tissue banks (REC Ref 11/AL/0174) for
provision of samples for HPV related research after approval from an
Independent Scottish HPV Archive Steering Committee. For this study our HPV
Archive Application was Reference 0004. The cervical samples used in this study
were obtained from different collections within the Scottish HPV Archive.
Cytology normal samples were from residual samples from National HPV
Surveillance Programme (Opt-out consent through the screening programme
approved by Tayside Research Ethics Committee Ref 11/AL/0174) and the
abnormals from two previously collected research projects (EAS, Scotland A
Research Ethics Committee Ref 07/S0501/92, and COHGS Scotland A Research
Ethics Committee Ref 09/S0801/106). Additionally, sections from 10 anonymised,
formalin fixed cervical biopsies from women with SCCC and 10 normal cervical
biopsies from women who had undergone hysterectomy for benign reasons were
obtained from the Royal Infirmary of Edinburgh Pathology Department Archive,
via the South East Scotland (Lothian) SAHSC Bioresource. The NHS Lothian
Biomarkers for Human Papillomavirus+ve Pre-Neoplastic Cervical Disease
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SAHSC Bioresource holds RTB approval from the East of Scotland REC,
(reference number 13/ES/0126) and provides samples with approval of the Tissue
Governance Committee.
Samples
For most samples with abnormalities, information on both cytology and histology
was available (see Table 1 for details). In addition, sections from 10 anonymised,
formalin fixed cervical biopsies from women with SCCC and 10 normal cervical
biopsies from women who had undergone hysterectomy for benign reasons were
obtained from the Royal Infirmary of Edinburgh Pathology Department Archive,
via the East of Scotland Bioresource.
HPV Genotyping
All cervical samples were genotyped for HPV status. Automated extraction of
DNA from LBC samples was performed used the MDX media Kit (Qiagen,
Manchester, UK). DNA was extracted from 10mm sections cut from the biopsies
using QIAamp DNA Mini Kit (Qiagen, UK) following the manufacturer’s
instructions. As we have previously published [22], genotyping was performed
using the Multimetrix HPV Assay (Diamex, Heidelberg, DE). This assay is based
on luminex technology and is capable of detecting 18 high-risk or putatively high-
risk types and 5 low-risk types according to the current IARC classification.
Among the HR-HPV+ve cervical samples or biopsies, 69% overall contained
either or both types 16 and 18. All 10 biopsies from women with SCCC were HR-
HPV+ve; of the 10 cervical biopsies from women who had undergone
hysterectomy for benign reasons, 8 were HPV-ve and 2 were HR-HPV+ve. All
LBC samples from women with CIN1, CIN2 or CIN3 were HR-HPV+ve; of the
LBC samples with normal morphology, 28 were HPV-ve, and, 9 were HR-
HPV+ve (Table 1).
Proteomic array
Since the collection medium ThinPrep preservcyt contains 50% methanol we used
a methanol/chloroform based protein extraction method. Briefly, 100ml ice cold
chloroform was added to 900ml of sample in an Eppendorf tube on ice, vortexed,
incubated on ice for 5min and spun for 5min at 10,000rpm at 4 C˚ in a benchtop
microfuge. The aqueous top layer was discarded, 300ml methanol was added and
the tube vortexed, and spun for 10 min at 10,000rpm at 4 C˚ in a benchtop
microfuge. The supernatant was removed and the pellet resuspended in 100ml Tris
Buffered Saline. Protein concentration was determined by Pierce BCA assay
(Thermo Scientific, UK). Antibody-based, pluripotent stem cell proteomic arrays
(Cat No. ARY010, R&D Systems, UK) were carried out as per manufacturer’s
instructions. To identify proteins of interest, for the arrays, pools of samples were
compared. Each pool contained 10mg of protein from each individual sample (see
Biomarkers for Human Papillomavirus+ve Pre-Neoplastic Cervical Disease
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Results). Developed arrays were scanned and pixel density calculated using Image-
J software.
Flow cytometry
A) Staining protocol: -1 ml aliquots from LBC samples in Preservcyt were passed
through a BD Falcon filter-top 5 ml FACS tube (BD Biosciences), to produce a
filtered cell suspension. This was then centrifuged at 3006g in a bench top
microfuge, the supernatant removed, and the pellet re-suspended in 400ml
MACSQuant running buffer (Miltenyi Biotec Ltd, UK) (‘‘buffer’’). 200ml of cell
suspension was stained with either isotype control (PE—IgM), or anti-TRA-1-60-
PE (both Miltenyi Biotec). Additionally, 5ml of the DNA chelating fluorescent dye,
DRAQ5 (Biostatus, UK) at 1:20 dilution was added to all samples. Samples were
incubated for 15 minutes at room temperature in the dark and then directly
analysed (with no further washing) using a MACSQuant Vyb or MACSQuant 10
flow cytometer (Miltenyi Biotec). The entire 200ml of sample was acquired per
tube. Samples were analysed using MACSQuantify software v2.4. Area and height
were collected for all parameters, antibody stained samples were acquired on a
hyper log (bi-exponential) scale, and DRAQ5 was acquired on a linear scale.
B) Analysis protocol: - Fig. 1 shows representative histograms outlining the
gating strategy for analysis. As samples contained variable amounts of debris,
initial gating was carried out using an SSC versus DRAQ5 gate to exclude any
events which did not contain nuclear material (Fig. 1A). Doublets were then
excluded from the analysis by gating DRAQ5 area versus height (Fig. 1B). The
singlet gate was then used to generate an SSC vs. PE plot (Fig. 1C&D) and a DNA
histogram for cell cycle analysis (Fig. 1E&F). Due to variability in the material
analysed, DNA histograms were analysed as a simplified percentage of events in
the G0/G1peak versus the S/G2/M peak. Positive staining with TRA-1-60-PE was
determined after subtracting the appropriate isotype background.
qRT-PCR for SOX2, HCG and TP63.
RNA was extracted from 1.5 ml aliquots of LBC samples using miRNeasy mini kit
(Qiagen, UK) following the manufacturer’s instructions. RNA was quantified on a
Table 1. Disease status, age range and cytology results for cervical LBC samples obtained from the Scottish national HPV Archive.
HPV & Disease (cytology/biopsy) Status No. Age in years Cytology result, dyskaryosis
range median None n5 mild n5 moderate n5 severe n5
unknown
n5
HPV -ve cyto -ve 28 20–34 20 28 0 0 0 0
HR-HPV +ve cyto -ve 9 20–43 20 9 0 0 0 0
HR-HPV +ve CIN 1 13 22–40 23 1 6 0 0 7
HR-HPV +ve CIN 2 22 20–28 23 0 12 6 1 3
HR-HPV +ve CIN 3 23 20–25 23 0 0 3 17 2
doi:10.1371/journal.pone.0115379.t001
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Fig. 1. Sample Flow Cytometry analysis showing gating strategy. Debris (no DNA stain) and cell clumps (high SSC) are excluded from the analysis (A).
Doublets excluded by plotting DRAQ5 area versus height (B). (C) and (D), Cells in HPV-ve normal samples do not stain with anti-TRA-1-60 but strong
staining is seen in some samples from women with CIN3 (gates set against individual sample isotype controls). (E) and (F), representative cell cycle profiles
Biomarkers for Human Papillomavirus+ve Pre-Neoplastic Cervical Disease
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Nanodrop spectrophotometer and stored at 280 C˚ until use. cDNA was made
from 500 ng RNA using the Quantitect Reverse Transcription Kit (Qiagen, UK) as
per manufacturer’s instructions and stored at 220 C˚ until use. Duplex qPCR was
carried out in Lightcycler Nano (Roche) realtime PCR system in duplicate in 8
well PCR strips using plates, primers, probes and reagents from Life Technologies
Applied Biosystems, UK. Wells contained 2ml cDNA, 1ml gene of interest primer
mix, 0.12ml each of 18S forward and reverse primers, 1.6ml 18S probe, and 13ml
mastermix. The PCR programme was 2 min at 50 C˚, 10 min at 95 C˚, followed by
40 cycles of 15 sec at 95 C˚ and 1 min at 60 C˚.
Immunohistochemistry
Sections (4mm) from formalin fixed, paraffin embedded cervical biopsies were
dewaxed in xylene and rehydrated through alcohol to water. Antigen retrieval was
performed in 0.9 M citrate buffer in a pressure cooker in an 800W microwave
oven for 15 minutes at full power. After cooling, slides were blocked with avidin-
biotin block followed by protein block (Insight Biotechnology Ltd, UK) and
stained with goat-anti-SOX2 antibody (R&D Systems, UK) or mouse monoclonal
anti-TP63 antibody (AbCam, UK) overnight at 4 C˚. Sections were then washed,
incubated with rabbit polyclonal biotinylated anti-goat or anti-mouse IgG (Vector
Labs, UK), washed, incubated with streptavidin-HRP, washed and colour
developed using DAB solution (Vector Labs). Sections stained with only
secondary antibody (no primary control) were included in each run. Parallel
sections from 11 cases were stained with SOX2 and TP63. Tumour cells were
evaluated for their nuclear expression of the transcription factors. There was no
significant difference between TP63 and SOX2 levels (Wilcoxon ranked pairs test).
For each section stained, five fields were photographed at 6200 magnification.
Using the ImageJ software ‘‘cell counter’’ plug-in, each picture was overlaid with a
grid and nuclear +ve and –ve tumour cells counted. At least 150 cells per field (750
per section) were counted.
Statistical analysis
Data were analysed with Graphpad Prism software. The Kruskall Wallis test with
Dunn’s multiple comparison post-test was used to compare normal and all disease
grade groups. To compare two groups the Mann-Whitney test or Wilcoxon
Ranked Pairs test was used as appropriate. Significance was assumed if p was
,0.05.
from an HPV-ve normal sample (E) and a sample from a patient with CIN3 (F), showing an increased G2/M peak in (F).
doi:10.1371/journal.pone.0115379.g001
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Results
Proteins associated with cancer stem cells can be detected in LBC
samples from patients with CIN3
To determine whether cancer stem cell related proteins were detectable in LBC
samples, we used a proteomic microarray for human stem cell proteins. The arrays
were carried out on pooled HR-HPV –ve samples from 9 women with no disease
and on pooled HR-HPV+ve samples from 9 women with CIN3. Arrays were
developed as described in Materials and Methods and pixel density of individual
spots analysed on inverted images (Fig. 2) with Image-J software. A number of
proteins including HCG, TP63 and SOX-2 were upregulated in the pooled
samples from patients with CIN3 compared to the pooled samples with normal
morphology. To validate this finding further samples that were either cytologically
normal and HR-HPV-ve, or HR-HPV+ve with severe dyskaryosis, were
individually evaluated for SOX2, TP63 and HCG mRNA by qRT-PCR. All three
mRNAs were elevated in samples with severe dyskaryosis (Fig. 2).
Flow cytometry shows increased TRA-1-60+ve cells in LBC
samples from patients with CIN3
We next investigated whether flow cytometry would be a practical methodology
for the detection of markers associated with cancer stem cells in cervical samples.
Most of these proteins are intracellular and preliminary attempts to stain for
NANOG and OCT4 revealed that background staining is a problem with
intracellular proteins (not shown) in these samples. For this reason, we
concentrated on detection of the cell surface carbohydrate epitope of podocalyxin
detected by the antibody TRA-1-60. Fig. 3 shows that overall, LBC samples from
patients with HR-HPV+ve CIN3 s had a small but significant increase in the
number TRA-1-60+ve cells compared to LBC samples with normal morphology
that were either HR-HPV +ve or -ve.
Flow cytometry indicates increased numbers of cycling cells in
LBC samples with high grade disease stratified by either biopsy
or cytology result
Cell cycle was detected by analysing staining with the DNA chelating dye DRAQ5.
Cycling cells were determined to be in the S+G2M phase of the cell cycle as
described in Materials and Methods. No aneuploid cells were detected in any
samples and cell cycle stages were comparable between samples. Fig. 4 shows that
significant increases were seen in cervical samples from women with significant
disease compared to normal samples regardless of whether normal samples were
HPV-ve or HPV+ve and regardless of whether significant disease was stratified as
biopsy proven CIN3 (Fig. 4A) or by cytology determined severe dyskaryosis
(Fig. 4B).
Biomarkers for Human Papillomavirus+ve Pre-Neoplastic Cervical Disease
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Fig. 2. Proteomic array detection of stem cell associated proteins in pooled aliquots from 9 HR-
HPV+ve cervical samples from women with CIN3 (A) and 9 HPV –ve samples with normal cytology (B);
(C & D) map and key for array spots; (E) average pixel density ranked by ratio of pooled CIN3:normal
samples for each protein on the array; (F) sox2, TP63 and HCG mRNAs are upregulated in HPV+ve
cervical samples with severe dyskaryosis compared to HPV–ve samples with normal morphology
(*5p,0.05, ** p,0.01, Mann Whitney test).
doi:10.1371/journal.pone.0115379.g002
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Stem cell marker expression is further increased in HR-HPV+ve
LBC samples from patients with CIN3 that had the highest
numbers TRA-1-60+ve cells.
To determine whether or not the 3 samples with the highest number of TRA-1-
60+ve cells represented a subset of the CIN3 cases with potentially higher cancer
stem cell presence, an equal amount of protein from each of these samples was
pooled and compared to an equivalent pool of proteins from 3 samples with HR-
HPV+ve CIN3 that showed no increase in TRA-1-60 using the same proteomic
array. Flow cytometry results for the samples selected are shown in Fig. 5a. The
three cases with increased TRA-1-60 +ve cells show similar numbers of cycling
cells to the other CIN3 cases used for this analysis. Fig. 5b shows that there was an
enhancement of signal for HCG, TP63 and SOX2 when the samples from the
CIN3 cases with increased TRA-1-60+ve cells were compared to the other CIN3
cases.
SOX2 and TP63 are strongly expressed in tumour cells in HR-
HPV+ve cervical cancer biopsies
To further validate the observation that enhanced SOX2 and/or TP63 protein in
cervical samples, from women with high grade pre-neoplastic cervical disease,
might relate to tumour progression, we stained a series of parallel sections from
cervical biopsies from 11 women with HR-HPV+ve SCCC and 11 women with
normal cervical tissue with anti-SOX2 and anti-TP63 antibodies. Fig. 6 shows
representative staining. Both antibodies stained the basal layers of squamous
epithelium in normal cervix and identified tumour cells in SCCC biopsies. Image
analysis of the % of tumour cells staining revealed that the majority of tumour
cells were positive for each marker and that there was no significant difference
Fig. 3. Cervical samples from women with CIN3 have increased numbers of TRA-1-60+ve cells
detected by flow cytometry (see Materials and Methods for details), 1 way ANOVA (Kruskall Wallis test
with Dunn’s post-test versus HPV+ve normal group), *5 p,0.05.
doi:10.1371/journal.pone.0115379.g003
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(p50.83) between the % cells stained with SOX2 (83.7¡3.9) and the % cells
stained with TP63 (80.2¡3.9) (Fig. 6).
Discussion
Up-regulation of hCG is reported in a number of cancers including SCCC [23]
and is associated with poor prognosis [24]. TP63 is a homologue of the tumour
suppressor protein TP53. In adult epithelial stem cells TP63 is a master regulator
for the proliferative potential of these cells [25] and interacts with SOX2 in
squamous cell carcinomas [26]. The detection of TP63 in proliferating basal
Fig. 4. Flow cytometric detection of cycling cells in cervical samples. (A) LBC samples stratified by HPV
status and histology; samples from women with CIN3 are significantly different from samples with normal
cytology and from CIN1 and CIN2, 1 way ANOVA (Kruskall Wallis test with Dunn’s post-test versus CIN3
group); (B) LBC samples stratified by HPV status and cytology results only; samples with severe dyskaryosis
are significantly different from all normal samples 1 way ANOVA (Kruskall Wallis test with Dunn’s post-test
versus severe disease group). * p5,0.05, ** p5,0.01, *** p5,0.001.
doi:10.1371/journal.pone.0115379.g004
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squamous cells has been noted in various cancers [27] including breast [28],
prostate [29], and cervical cancer [30, 31]. TP63 has also been implicated as a
biomarker of cervical disease progression [32].
SOX2 is a core transcriptional regulator of pluripotency in mouse and human
embryonic stem cells [33] and its transient expression together with OCT4, KLF4
and C-MYC in adult somatic cells is sufficient to reverse the developmental clock,
to generate reprogrammed induced pluripotent stem cells [34]. Following
embryonic development, SOX2 has also been shown to be required for the
maintenance of adult stem cells residing in various tissues of the body including
the gut [35], the skin [36], the eye lens and the cervix [37]. SOX2 is important in
epithelial cell differentiation and is expressed in basal epithelium of the tongue
[38] and in tongue squamous cell carcinoma [39]. Gene analysis has identified
SOX2 and TP63 gene expression as important in defining molecular subtypes in
HPV related head and neck cancer [40] and SOX2 has been associated with a
number of other human cancers [41–43] including cervical cancer [44]. Recently,
Fig. 5. Samples with increased TRA-1-60+ve cells from patients with CIN3 have enhanced expression
of stem cell proteins. A) Flow cytometric analysis of samples used for proteomic microarray. Dotted lines
show that the three samples with a significant increase in TRA-1-60 +ve cells have similar levels of cycling
cells to the other three CIN3 samples. * 5p,.05. B) Image-J pixel density analysis of stem cell proteomic
microarray. SOX2, TP63 and HCG are further increased in samples with increased TRA-1-60+ve cells. C)
Inverted image of the scan of the array from TRA1-60+ve samples; D) Inverted image of the scan of the array
from TRA1-60 –ve samples.
doi:10.1371/journal.pone.0115379.g005
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in a murine skin cancer model SOX2 was shown to be a marker of CSCs in both
pre-neoplastic and invasive skin cancer [36].
Our data support the previous findings that increased expression of both SOX2
and TP63 are associated with dysregulated cell growth in the epithelial
compartment of the cervix. Furthermore, our data suggest identifiable changes in
their expression in cervical samples from women with high grade pre-neoplastic
disease.
We also showed by flow cytometry that some HR-HPV positive samples from
patients with CIN3 have increased numbers of cells that are positive for the cell
surface stem cell marker TRA-1-60. Also, these samples demonstrate further
enhancement of HCG, TP63 and SOX2 relative to samples from patients with
CIN3 that did not show enhanced TRA-1-60. This indicates that samples from
patients with CIN3 contain detectable cancer stem cell markers. SOX2, HCG and
Fig. 6 TP63 and SOX2 staining in cervical biopsies. Immunohistochemical staining of cervical biopsies.
Bars 5 50mm.(A) normal cervix no primary control; (B) normal cervix stained with anti-SOX2; (C) Squamous
cell cervical carcinoma no primary control; (D) representative TP63, and (E) representative SOX2, staining of
tumour cells. For both TP63 and SOX2 staining was seen in the nucleus of positive cells (examples indicated
by solid arrows); negative cells were a minority of tumour cells (examples indicated by unfilled arrows). (F)
Image analysis results of % nuclear +ve tumour cells in biopsies. Parallel sections from 11 cases were stained
with SOX2 and TP63. Tumour cells were evaluated for their nuclear expression of the transcription factors.
There was no significant difference between the data for SOX2 and TP63 (Wilcoxon signed rank test).
doi:10.1371/journal.pone.0115379.g006
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TP63 mRNAs were also shown to be upregulated in cervical samples with HR-
HPV+ve high grade dyskaryosis and SOX2 and TP63 immunohistochemistry
identified cancerous cells, in HR-HPV+ve biopsies, from women with cervical
squamous cell carcinoma. Flow cytometric analysis of numbers of cycling cells in
cervical samples also differentiated normal from high grade disease, regardless of
the HPV status of the normal samples, indicating that the increase was disease and
not simply HPV-infection related. The increase in numbers of cycling cells was
seen whether high grade disease was based on histological examination of a biopsy
or on cytology only. This indicates that this testing modality might be applicable
in a wider screening context as a laboratory triage test for significant disease.
Although there are disturbances in cell cycle control associated with cervical
cancer [45], it has been reported that the vast majority of cases are diploid [46].
We found no evidence of aneuploidy in the LBC samples tested from HR-HPV+ve
women with high grade disease.
TRA-1-60 is a carbohydrate epitope of the cell surface sialylated keratan sulfate
proteoglycan podocalyxin [18, 47] found in human stem cells [18], cancer stem
cells [48] and embryonal cancers [49]. Podocalyxin prevents cell adhesion and
promotes metastasis. Overexpression is associated with poor prognosis in a
number of cancers including breast [50], ovarian [51], renal [52] and uterine [53]
cancers. Although podocalyxin has not previously been reported in cervical
cancer, it interacts with a protein, ezrin [54], which has been reported to be
upregulated in HR-HPV associated cervical lesions where it was found to co-
localise with p16inc [55]. Furthermore ezrin overexpression has been reported in
cervical cancer biopsies [56]. Podocalyxin has been shown to increase metastatic
potential of tumour cells, in vitro, through its interaction with ezrin [57].
We chose to stain SOX2 protein in these biopsies as it has been reported to be
upregulated in human cervical cancer stem cells [58] and in SCCC [44]. Normal
cervical squamous epithelium showed basal cell staining and all SCCC biopsies
showed similar staining of tumour cells, but not stromal cells. Although the SOX2
protein is normally confined to the nucleus, we found that in the cancer cells,
there was both nuclear and cytoplasmic expression, which may indicate abnormal
accumulation of the protein in tumour cells. TP63 has also been shown to be
expressed in cervical cancer [59] and interacts with SOX2 in squamous cell
carcinomas [26] we also stained for TP63 protein in parallel sections from the
same biopsies. Our results show that SOX2 and TP63 proteins are found in the
nucleus of most tumour cells in HR-HPV+ve SCCC biopsies. To our knowledge
this is the first time SOX2 and TP63 have been evaluated in the same series of
cases with this disease.
Our results indicate that detection of cancer stem cell associated proteins by
flow cytometry or western blotting and/or flow cytometric detection of numbers
of cycling cells may be useful laboratory tests for triage of HR-HPV+ve cervical
samples for significant cervical disease. They further indicate that SOX2 and TP63
immunohistochemistry may have value in diagnosis of HR-HPV related SCCC. It
is not possible to follow up any of the patients in this study but it would be of
obvious interest in the future to determine the longterm outcome of patients with
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pre-neoplastic lesions whose cervical samples show increased CSC marker
expression and/or numbers of proliferative cells.
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